Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of pasireotide with or without cabergoline in Cushing's disease
2013-002170-49Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of pasireotide LAR in Corticotropin adenoma (ACTHoma) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of patients with normalized mUFC at week 35. Started Sep 2013; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2013-002170-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002170-49.